Instrumentl eFile Render
Object ID: 202103169349312140 - Rendered 2024-05-07
TIN: 91-1157127
Form
990
Department of the Treasury
Internal Revenue Service
Return of Organization Exempt From Income Tax
Under section 501(c), 527, or 4947(a)(1) of the Internal Revenue Code (except private foundations)
Do not enter social security numbers on this form as it may be made public.
Go to
www.irs.gov/Form990
for instructions and the latest information.
OMB No. 1545-0047
20
20
Open to Public Inspection
A
For the 2020 calendar year, or tax year beginning
01-01-2020
, and ending
12-31-2020
B
Check if applicable:
Address change
Name change
Initial return
Final return/terminated
Amended return
Application pending
C
Name of organization
PATH
Doing business as
Number and street (or P.O. box if mail is not delivered to street address)
2201 WESTLAKE AVENUE NO 200
Room/suite
City or town, state or province, country, and ZIP or foreign postal code
SEATTLE
,
WA
98121
D Employer identification number
91-1157127
E Telephone number
G
Gross receipts $
357,796,602
F
Name and address of principal officer:
KELLY PRIESTLEY
2201 WESTLAKE AVENUE NO 200
SEATTLE
,
WA
98121
I
Tax-exempt status:
501(c)(3)
501(c)
(
)
(insert no.)
4947(a)(1)
or
527
J
Website:
WWW.PATH.ORG
H(a)
Is this a group return for
subordinates?
Yes
No
H(b)
Are all subordinates
included?
Yes
No
If "No," attach a list. (see instructions)
H(c)
Group exemption number
K
Form of organization:
Corporation
Trust
Association
Other
L
Year of formation:
1981
M
State of legal domicile:
WA
Part I
Summary
1
Briefly describe the organization’s mission or most significant activities:
SEE PART III, LINE 1.
2
Check this box
3
Number of voting members of the governing body (
Part VI
, line 1a)
........
3
15
4
Number of independent voting members of the governing body (
Part VI
, line 1b)
.....
4
15
5
Total number of individuals employed in calendar year 2020 (
Part V
, line 2a)
......
5
714
6
Total number of volunteers (estimate if necessary)
.............
6
0
7a
Total unrelated business revenue from
Part VIII
, column (C), line 12
........
7a
0
b
Net unrelated business taxable income from Form 990-T, line 39
.........
7b
0
Prior Year
Current Year
8
Contributions and grants (
Part VIII
, line 1h)
.........
286,808,545
287,454,383
9
Program service revenue (
Part VIII
, line 2g)
.........
2,038
0
10
Investment income (
Part VIII
, column (A), lines 3, 4, and 7d )
....
6,723,428
12,502,251
11
Other revenue (
Part VIII
, column (A), lines 5, 6d, 8c, 9c, 10c, and 11e)
836,870
1,030,112
12
Total revenue—add lines 8 through 11 (must equal
Part VIII
, column (A), line 12)
294,370,881
300,986,746
13
Grants and similar amounts paid (
Part IX
, column (A), lines 1–3 )
...
55,619,080
67,994,827
14
Benefits paid to or for members (
Part IX
, column (A), line 4)
.....
0
0
15
Salaries, other compensation, employee benefits (
Part IX
, column (A), lines 5–10)
131,590,498
132,096,396
16a
Professional fundraising fees (
Part IX
, column (A), line 11e)
.....
0
0
b
Total fundraising expenses (
Part IX
, column (D), line 25)
2,409,886
17
Other expenses (
Part IX
, column (A), lines 11a–11d, 11f–24e)
....
105,099,261
92,968,260
18
Total expenses. Add lines 13–17 (must equal
Part IX
, column (A), line 25)
292,308,839
293,059,483
19
Revenue less expenses. Subtract line 18 from line 12
.......
2,062,042
7,927,263
Beginning of Current Year
End of Year
20
Total assets (
Part X
, line 16)
.............
243,064,155
283,556,203
21
Total liabilities (
Part X
, line 26)
.............
204,045,574
234,982,056
22
Net assets or fund balances. Subtract line 21 from line 20
.....
39,018,581
48,574,147
Part II
Signature Block
Sign Here
Under penalties of perjury, I declare that I have examined this return, including accompanying schedules and statements, and to the best of my knowledge and belief, it is true, correct, and complete. Declaration of preparer (other than officer) is based on all information of which preparer has any knowledge.
Signature of officer
Date
Type or print name and title
Paid Preparer Use Only
Print/Type preparer's name
Preparer's signature
Date
Check
if
self-employed
PTIN
Firm's name
Firm's EIN
Firm's address
Phone no.
May the IRS discuss this return with the preparer shown above? (see instructions)
..........
Yes
No
For Paperwork Reduction Act Notice, see the separate instructions.
Cat. No. 11282Y
Form
990
(2020)
Form 990 (2020)
Page
2
Part III
Statement of Program Service Accomplishments
Check if Schedule O contains a response or note to any line in this
Part III
..............
1
Briefly describe the organization’s mission:
PATH'S MISSION IS TO ADVANCE HEALTH EQUITY THROUGH INNOVATION AND PARTNERSHIPS. (CONTINUED ON SCHEDULE O)
2
Did the organization undertake any significant program services during the year which were not listed on
the prior Form 990 or 990-EZ?
.....................
Yes
No
If "Yes," describe these new services on Schedule O.
3
Did the organization cease conducting, or make significant changes in how it conducts, any program
services?
...........................
Yes
No
If "Yes," describe these changes on Schedule O.
4
Describe the organization’s program service accomplishments for each of its three largest program services, as measured by expenses. Section 501(c)(3) and 501(c)(4) organizations are required to report the amount of grants and allocations to others, the total expenses, and revenue, if any, for each program service reported.
4a
(Code:
) (Expenses $
115,045,810
including grants of $
20,527,002
) (Revenue $
)
GLOBAL HEALTH PROGRAMS: PATH'S GLOBAL HEALTH PROGRAMS DIVISION IS RESPONSIBLE FOR PATH'S SCIENTIFIC EXPERTISE IN MALARIA AND NEGLECTED TROPICAL DISEASES; HIV AND TUBERCULOSIS; MATERNAL, NEWBORN, AND CHILD HEALTH AND NUTRITION; SEXUAL AND REPRODUCTIVE HEALTH; AND NONCOMMUNICABLE DISEASES. THE DIVISION ALSO OVERSEES PATH'S WORK IN HEALTH SYSTEMS INNOVATION AND DELIVERY, AND MANAGES OUR COUNTRY OFFICES.(CONTINUED ON SCHEDULE O)MALARIA AND NEGLECTED TROPICAL DISEASESPATH PARTNERS WITH GOVERNMENTS, THE PRIVATE SECTOR, AND FUNDERS ACROSS THE GLOBE TO BRING THE WORLD CLOSER TO MALARIA ERADICATION. OUR MALARIA AND NEGLECTED TROPICAL DISEASES PROGRAM INCLUDES MORE THAN 100 PATH STAFF MEMBERS IN MORE THAN TEN COUNTRIES. OUR STRATEGY INCLUDES OPTIMIZING THE DELIVERY OF CURRENT TOOLS AND APPROACHES TO ENSURE THEY REACH THE PEOPLE WHO NEED THEM, DESIGNING NEW STRATEGIES AND DEVELOPING NEXT-GENERATION TOOLS TO OVERCOME EMERGING CHALLENGES, AND CREATING INNOVATIVE PARTNERSHIPS AND FUNDING MODELS TO ENSURE OUR PROGRAMS ARE SUSTAINABLE AND EFFECTIVE. PATH-PIONEERED APPROACHES HAVE CONTRIBUTED TO REMARKABLE PROGRESS IN MALARIA, WITH NEARLY 7 MILLION LIVES SAVED SINCE 2000.IN 2020, OUR MALARIA CONTROL AND ELIMINATION PARTNERSHIP IN AFRICA (MACEPA) PROGRAM CONTINUED TO SUPPORT THE GOVERNMENTS OF ETHIOPIA, SENEGAL, AND ZAMBIA TOWARD THEIR MALARIA ELIMINATION GOALS. MACEPA'S WORK INCLUDED EVALUATING THE LATEST, MOST SENSITIVE DIAGNOSTIC TESTS; ESTABLISHING RAPID REPORTING SYSTEMS; AND CONTINUING TO SUPPORT POPULATION-WIDE, DRUG-BASED STRATEGIES SUCH AS MASS DRUG ADMINISTRATION. WITH A NEW GRANT FROM THE BILL & MELINDA GATES FOUNDATION, MACEPA BEGAN IDENTIFYING OPPORTUNITIES IN ADDITIONAL HIGH-MALARIA-BURDEN GEOGRAPHIES SUCH AS THE DEMOCRATIC REPUBLIC OF THE CONGO (DRC), MALAWI, MALI, AND NIGERIA.PATH WAS ALSO AWARDED AN ADD-ON TO OUR PROGRAM FOR THE ADVANCEMENT OF MALARIA OUTCOMES (PAMO), FUNDED BY THE US PRESIDENT'S MALARIA INITIATIVE (PMI). CALLED PAMO PLUS, THE PROJECT CONTINUES ITS PREDECESSOR'S MISSION OF ASSISTING THE GOVERNMENT OF ZAMBIA TO ELIMINATE MALARIA WITHIN ITS BORDERS. IN 2020, PAMO PROVIDED TECHNICAL SUPPORT AND MENTORSHIP TO MORE THAN 2,000 HEALTH CARE PROVIDERS AND TRAINED 1,098 COMMUNITY HEALTH WORKERS AND THEIR 272 SUPERVISORS IN COMMUNITY-LEVEL CASE MANAGEMENT AND SURVEILLANCE. PAMO/PAMO PLUS ALSO SUPPORTED THE DISTRIBUTION OF 122,602 INSECTICIDE-TREATED BEDNETS, ORGANIZED SOCIAL BEHAVIOR CHANGE ACTIVITIES (INCLUDING IN SCHOOLS), AND PROVIDED TECHNICAL AND MATERIAL SUPPORT FOR DATA QUALITY AUDITS IN HEALTH FACILITIES.PATH CONTINUED TO EVALUATE NEW VECTOR CONTROL TOOLS IN 2020 WITH OUR PARTNERS UNDER PMI VECTORLINK, THE US AGENCY FOR INTERNATIONAL DEVELOPMENT'S (USAID'S) FLAGSHIP MALARIA VECTOR CONTROL PROJECT. SIMILARLY, UNDER THE NEW NETS PROJECT FUNDED BY UNITAID AND THE GLOBAL FUND TO FIGHT AIDS, TUBERCULOSIS AND MALARIA, WE HELPED GENERATE EVIDENCE FOR THE ADOPTION OF BEDNETS EFFECTIVE AGAINST PYRETHROID-RESISTANT MOSQUITOES. IN ZAMBIA, PATH LED THE DESIGN AND IMPLEMENTATION OF LABORATORY AND FIELD ACTIVITIES TO TEST ANOTHER NEW TOOL FOR MALARIA VECTOR CONTROL, THE ATTRACTIVE TARGETED SUGAR BAIT (ATSB); WE ALSO COORDINATED PARTNERS WORKING ON ATSB RESEARCH IN KENYA, MALI, AND ZAMBIA, TOGETHER WITH ISRAEL-BASED MANUFACTURER WESTHAM LTD. AND UK-BASED FUNDER INNOVATIVE VECTOR CONTROL CONSORTIUM. IN ADDITION, PATH LED A USAID INITIATIVE TO SUPPORT US GOVERNMENT INVESTMENTS IN MALARIA OPERATIONAL RESEARCH AND PROGRAM EVALUATION. UNDER THE PMI INSIGHTS PROJECT, PATH COORDINATED THE WORK OF SEVERAL PARTNERS TO STRENGTHEN POLICIES, STRATEGIES, AND GUIDELINES FOR MALARIA CONTROL AND ELIMINATION INTERVENTIONS. IN SENEGAL AND DRC, PATH BEGAN WORK TO INTEGRATE THE DATA VISUALIZATION DASHBOARDS OF THE NATIONAL EMERGENCY OPERATIONS CENTERS AND NATIONAL MALARIA CONTROL PROGRAMS AND DEVELOP IN-COUNTRY CAPACITY FOR DATA USE. THESE EFFORTS HELPED BOTH COUNTRIES RESPOND TO COVID-19 AND MITIGATE THE VIRUS' IMPACT ON MALARIA CONTROL AND ELIMINATION. PATH AND A PRIVATE-SECTOR TECHNOLOGY PARTNER, BLUESQUARE, SUPPORTED THE DRC MINISTRY OF HEALTH (MOH) TO STRENGTHEN COVID-19 CASE TRACKING AND CONTACT TRACING.AT THE ONSET OF COVID-19, THE PATH LABORATORY TEAM IN ZAMBIA PIVOTED FROM MALARIA TO WHOLE GENOME SEQUENCING OF SARS-COV-2 (THE VIRUS RESPONSIBLE FOR COVID-19) THROUGH FUNDING FROM THE BILL & MELINDA GATES FOUNDATION AND IN COLLABORATION WITH THE UNIVERSITY OF ZAMBIA SCHOOL OF VETERINARY MEDICINE. THE LABORATORY'S WORK ENABLED IDENTIFICATION OF THE BETA (B.1.351) VARIANT OF CONCERN IN ZAMBIA, WHICH WAS ASSOCIATED WITH A MAJOR SECOND WAVE OF COVID-19 IN THE COUNTRY. THE LABORATORY'S WORK ALSO LED TO ESTABLISHMENT OF A NATIONAL SPECIMEN COLLECTION SYSTEM THROUGH THE ZAMBIA NATIONAL PUBLIC HEALTH INSTITUTE.THE VIVACCESS PROJECT, WHICH FOCUSES ON RADICAL CURE (ELIMINATION OF DORMANT LIVER-STAGE PARASITES) OF PLASMODIUM VIVAX MALARIA, CONTINUED TO SUPPORT INTRODUCTION OF G6PD TESTS AND OTHER RADICAL CURE PRODUCTS IN BRAZIL, CAMBODIA, COLOMBIA, ETHIOPIA, INDIA, LAOS, MYANMAR, PERU, THAILAND, AND VIETNAM. VIVACCESS ENGAGED WITH NORMATIVE POLICY BODIES SUCH AS THE WORLD HEALTH ORGANIZATION (WHO), PROMOTED MULTISTAKEHOLDER DISCUSSIONS THROUGH REGIONAL AND GLOBAL EVENTS, AND MUCH MORE. (ADDITIONAL WORK IN MALARIA IS COVERED IN THE CENTER FOR VACCINE INNOVATION AND ACCESS SECTION.)PATH'S EFFORTS TO ELIMINATE NEGLECTED TROPICAL DISEASES CONTINUED IN 2020 IN THE DRC, WHERE WE WORKED TO COMBAT HUMAN AFRICAN TRYPANOSOMIASIS (HAT, OR "SLEEPING SICKNESS") IN COLLABORATION WITH THE COUNTRY'S NATIONAL PROGRAM FOR THE CONTROL OF HAT (PNLTHA). WITH FUNDING FROM THE BILL & MELINDA GATES FOUNDATION, PATH PROVIDED LOGISTICAL AND OPERATIONAL SUPPORT TO THE PNLTHA IN ACTIVE AND PASSIVE CASE DETECTION AND VECTOR CONTROL. WE ALSO SUPPORTED ADVOCACY, SENSITIZATION, AND PROMOTION ACTIVITIES TO STRENGTHEN HAT ELIMINATION EFFORTS AT THE NATIONAL, PROVINCIAL, AND COMMUNITY LEVELS. IN INDIA, PATH CONTINUED TO PROVIDE STRATEGIC TECHNICAL ASSISTANCE AT THE NATIONAL, STATE, AND SUB-STATE LEVELS. IN THE STATE OF UTTAR PRADESH, WE HELPED ENSURE TRANSMISSION OF VISCERAL LEISHMANIASIS STAYED AT OR BELOW ELIMINATION LEVEL IN ENDEMIC DISTRICTS THROUGH HIGH-QUALITY SURVEILLANCE, ACTIVE CASE DETECTION, AND VECTOR CONTROL. PATH ALSO PROVIDED TECHNICAL ASSISTANCE FOR LYMPHATIC FILARIASIS (ELEPHANTIASIS) ELIMINATION THROUGH MASS DRUG ADMINISTRATION AND HELPED ESTABLISH A TECHNICAL SUPPORT UNIT FOR DENGUE-CHIKUNGUNYA CONTROL AND MALARIA ELIMINATION. HIV AND TUBERCULOSISPATH'S HIV AND TUBERCULOSIS (TB) PROGRAMMING REACHES GENERAL POPULATIONS AS WELL AS KEY POPULATIONS AFFECTED BY HIV/TB.IN 2020, AS THE COVID-19 RESPONSE HINDERED ACCESS TO HEALTH FACILITIES IN MANY COUNTRIES, PATH MOVED RAPIDLY TO MINIMIZE THE IMPACT ON HIV AND TB SERVICES. PATH USED AN APPROACH OF PROTECT-MITIGATE-SUPPORT: UNDER THE "PROTECT" PILLAR, WE EQUIPPED AND TRAINED FRONTLINE HEALTH CARE PROVIDERS TO TRIAGE AND DELIVER SERVICES TO PEOPLE WITH COVID-19 EXPOSURE OR SYMPTOMS. UNDER THE "MITIGATE" PILLAR, WE ADAPTED WHERE AND HOW HIV AND TB SERVICES WERE OFFERED, SHIFTING TOWARD VIRTUAL, COMMUNITY, AND PRIVATE-SECTOR DELIVERY MODALITIES AND MULTI-MONTH DRUG DISPENSING TO REDUCE THE NEED FOR CLINIC VISITS. UNDER THE "SUPPORT" PILLAR, WE USED EXISTING HIV AND TB PLATFORMS TO DISSEMINATE INFORMATION ON COVID-19, AND WE ADAPTED TB SCREENING PROTOCOLS TO INCLUDE SCREENING AND TRIAGE FOR COVID-19 (AND VICE VERSA). IN THE DRC, UNDER THE USAID-FUNDED INTEGRATED HIV/AIDS PROJECT, PATH INTRODUCED ASSISTED HIV SELF-TESTING (HIVST) VIA PHARMACISTS, ALTERNATIVE MEDICINE PROVIDERS, AND COMMUNITY HEALTH WORKERS. WE TESTED APPROXIMATELY 180,000 PEOPLE, ENROLLED AROUND 12,400 NEWLY IDENTIFIED PEOPLE LIVING WITH HIV (PLHIV) ON ANTIRETROVIRAL THERAPY (ART), AND SUPPORTED MORE THAN 43,800 INDIVIDUALS TO CONTINUE TREATMENT. IN WESTERN KENYA, UNDER THE US PRESIDENT'S EMERGENCY PLAN FOR AIDS RELIEF-FUNDED AFYA ZIWANI PROJECT, PATH EVOLVED OUR APPROACH, PARTICULARLY FOR HIV-NEGATIVE AGYW. THE PROJECT CREATED WHATSAPP-BASED VIRTUAL SAFE SPACES AND MOBILE, HOME-BASED SAFE SPACES TO ENSURE AGYW CONTINUED TO RECEIVE INFORMATION, COUNSELING, AND OTHER SERVICES DURING THE COVID-19 PANDEMIC; WE ALSO USED THESE SPACES TO DISSEMINATE INFORMATION ON COVID-19. THE PROJECT HOME-DELIVERED APPROXIMATELY 800 HIV PRE-EXPOSURE PROPHYLAXIS REFILLS AND MORE THAN 8,000 HIVST KITS FOR AGYW, WITH NO HIV-POSITIVE RESULTS. ACROSS ALL POPULATION GROUPS, AFYA ZIWANI TESTED MORE THAN 140,000 PEOPLE FOR HIV, LINKED ABOUT 3,500 NEWLY IDENTIFIED PLHIV TO ART, AND SUPPORTED A COHORT OF 25,600 PEOPLE ON TREATMENT.
4b
(Code:
) (Expenses $
92,606,261
including grants of $
34,739,083
) (Revenue $
)
ESSENTIAL MEDICINES: PATH'S ESSENTIAL MEDICINES DIVISION DEVELOPS AND DELIVERS LIFESAVING VACCINES AND DRUGS FOR WOMEN, CHILDREN, AND COMMUNITIES AROUND THE GLOBE.(CONTINUED ON SCHEDULE O)CENTER FOR VACCINE INNOVATION AND ACCESSPATH'S CENTER FOR VACCINE INNOVATION AND ACCESS ALIGNS EXPERTISE ACROSS EVERY STAGE OF VACCINE RESEARCH, DEVELOPMENT, AND INTRODUCTION TO MAKE VACCINES AVAILABLE TO MORE COMMUNITIES, PARTICULARLY IN LOW- AND MIDDLE-INCOME COUNTRIES. OUR PORTFOLIO INCLUDES MORE THAN TWO DOZEN VACCINE PRODUCTS IN DEVELOPMENT OR ALREADY IN USE, WITH AN EMPHASIS ON THE LEADING INFECTIOUS CAUSES OF CHILD DEATH AND DISEASE WORLDWIDE. IN RESPONSE TO THE COVID-19 PANDEMIC, PATH MOBILIZED QUICKLY TO DEPLOY OUR END-TO-END IMMUNIZATION EXPERTISE. WE PROVIDED POLICY AND FINANCIAL ADVICE TO GAVI ON DESIGN OF THE COVAX FACILITY WITH THE GOAL OF EQUITABLE COVID-19 VACCINE ACCESS AND DELIVERY WORLDWIDE. WE SECURED INITIAL FUNDING TO ADVANCE A LOW-COST COVID-19 VACCINE CANDIDATE (NDV-HXP-S) BASED ON TECHNOLOGIES DEVELOPED BY THE ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI AND THE UNIVERSITY OF TEXAS AT AUSTIN THAT IS TARGETED FOR EMERGING COUNTRY VACCINE MANUFACTURERS. ACROSS THE COVID-19 VACCINE DEVELOPMENT ECOSYSTEM, WE SUPPORTED VACCINE DEVELOPMENT AND CLINICAL SITE READINESS; PROVIDED CHEMISTRY, MANUFACTURING, AND CONTROL EXPERTISE TO MANUFACTURERS; AND LENT OUR CLINICAL, TECHNICAL, AND REGULATORY EXPERTISE TO DEVELOPERS AND COVID-19 CONSORTIA.IN 2020, PATH CONTINUED TO PROVIDE TECHNICAL SUPPORT TO POLIO VACCINE MANUFACTURERS AND ADVANCE RESEARCH ON NEW INACTIVATED POLIO VACCINE AND ORAL POLIO VACCINE CANDIDATES. THE NOVEL ORAL POLIO VACCINE AGAINST TYPE 2 POLIOVIRUS (NOPV2) ACHIEVED A MAJOR MILESTONE WHEN IT BECAME THE FIRST VACCINE TO RECEIVE A WHO EMERGENCY USE LISTING (EUL). AS THE CONVENOR OF THE NOPV2 CONSORTIUM, PATH CONTRIBUTED KEY EVIDENCE AND SUPPORTED THE MANUFACTURER'S SUCCESSFUL EUL APPLICATION. THROUGHOUT 2020, PATH AND OUR COUNTRY PARTNERS EXPANDED COVERAGE OF JAPANESE ENCEPHALITIS (JE) VACCINATION AND DEVELOPED AND DISSEMINATED EVIDENCE TO SUPPORT JE VACCINE DECISION-MAKING. WRAPPING UP A REMARKABLE 17-YEAR GLOBAL PARTNERSHIP, PATH COMPLETED TWO STUDIES EXAMINING JE VACCINE DURATION OF PROTECTION AND CO-ADMINISTRATION AND FINALIZED A SUITE OF MATERIALS OUTLINING THE LESSONS AND STORY OF JE VACCINATION EFFORTS. ALSO IN 2020, WE CONTINUED A PIVOTAL, PHASE 3 STUDY OF A POLYVALENT MENINGOCOCCAL MENINGITIS CONJUGATE VACCINE. THE VACCINE, DEVELOPED BY SERUM INSTITUTE OF INDIA PVT. LTD., BUILDS ON THE SUCCESS OF MENAFRIVAC, A GROUNDBREAKING VACCINE AGAINST SEROGROUP A MENINGOCOCCAL MENINGITIS THAT WAS DEVELOPED THROUGH AN EARLIER PATH PARTNERSHIP. THE POLYVALENT VACCINE TARGETS SEROGROUPS A, C, W, X, AND Y. AS THE FIRST VACCINE TO TARGET SEROGROUP X, THE VACCINE HAS THE POTENTIAL TO ELIMINATE MENINGITIS EPIDEMICS FROM AFRICA'S "MENINGITIS BELT" REGION. WE ALSO CONTRIBUTED TECHNICAL AND STRATEGIC EXPERTISE TO THE GLOBAL "DEFEATING MENINGITIS BY 2030" INITIATIVE, WHICH CULMINATED IN WORLD HEALTH ASSEMBLY ADOPTION OF THE FIRST-EVER RESOLUTION ON MENINGITIS PREVENTION AND CONTROL AND ENDORSEMENT OF A GLOBAL ROAD MAP TO DEFEAT MENINGITIS.TO PREVENT MALARIA, PATH ACCELERATED THE DEVELOPMENT OF A WIDE VARIETY OF MALARIA VACCINE CANDIDATES AND APPROACHES. FOR EXAMPLE, WE WORKED WITH WHO AND OTHER PARTNERS, INCLUDING THE MINISTRIES OF HEALTH IN GHANA, KENYA, AND MALAWI, TO INTRODUCE THE WORLD'S FIRST MALARIA VACCINE, KNOWN AS RTS,S, IN SELECTED AREAS OF THOSE COUNTRIES. WE ALSO CONTINUED TO ADVANCE RESEARCH INTO WHETHER REDUCING THE DOSE LEVEL OF RTS,S AND DELAYING THE ADMINISTRATION OF DOSES HAS THE POTENTIAL TO FURTHER AID MALARIA ELIMINATION EFFORTS BY STRETCHING LIMITED VACCINE SUPPLIES AND PROTECTING AS MANY PEOPLE AS POSSIBLE. ADDITIONALLY, WORK CONTINUED ON EFFORTS TO IDENTIFY IMMUNE CORRELATES OF PROTECTION AND STUDY THE USE OF MONOCLONAL ANTIBODIES TO COMBAT MALARIA. IN 2020, PATH RECEIVED A FIVE-YEAR GRANT FROM USAID TO ADVANCE PRE-ERYTHROCYTIC, BLOOD-STAGE, AND COMBINATION MALARIA VACCINE CANDIDATE APPROACHES.THE DEFEAT DIARRHEAL DISEASE (DEFEATDD) INITIATIVE CONTINUED ITS ROLE AS A DIGITAL HUB FOR INFORMATION ON PREVENTING AND TREATING CHILDHOOD DIARRHEAL DISEASE. A MAJOR FOCUS OF 2020 WAS A CAMPAIGN TO MAINTAIN CHILD HEALTH INVESTMENTS DURING THE COVID-19 PANDEMIC, INCLUDING STEADY ACCESS TO ESSENTIAL MEDICINES AND ROUTINE IMMUNIZATION. IN ONGOING EFFORTS TO SUPPORT LOCAL VACCINE PRODUCTION, PATH SUPPORTED VIETNAM-BASED MANUFACTURER POLYVAC TO COMPLETE CLINICAL TRIALS FOR THE LIQUID FORMULATION OF ROTAVIN VACCINE. OUR PHASE 3 STUDY FOUND THAT ROTAVIN IS AS SAFE AND IMMUNOGENIC AS THE CURRENTLY LICENSED FROZEN FORMULATION, ROTAVIN-M1. WE COMPLETED THE CLINICAL PHASE OF A PHASE 1 STUDY IN THE UNITED STATES OF A NOVEL, INJECTABLE SUBUNIT SHIGELLA VACCINE CANDIDATE AND INITIATED FOLLOW-ON EXPLORATORY IMMUNOLOGY ANALYSES USING SAMPLES FROM THE STUDY. AND WE CONTINUED TO HELP INTRODUCE AND ADVANCE ACCESS TO CURRENTLY AVAILABLE ROTAVIRUS VACCINES.PATH CONTINUED TO ADVANCE PRECLINICAL DEVELOPMENT OF A VACCINE AGAINST GROUP B STREPTOCOCCUS, THE LEADING CAUSE OF BACTERIAL SEPSIS AND MENINGITIS IN YOUNG INFANTS WORLDWIDE. WE SUPPORTED INVENTPRISE, A BIOTECHNOLOGY COMPANY, AS IT WORKS TO DEVELOP A MULTIVALENT, CONJUGATE VACCINE FOR LOW- AND MIDDLE-INCOME COUNTRIES. THE INTENDED RECIPIENTS ARE PREGNANT WOMEN-PART OF A STRATEGY THAT BOOSTS IMMUNITY AGAINST THE BACTERIUM AND TRANSFERS PROTECTIVE ANTIBODIES TO THE DEVELOPING BABY. AS PART OF THE TYPHOID VACCINE ACCELERATION CONSORTIUM, PATH WORKED TO ADVANCE TYPHOID CONJUGATE VACCINE (TCV) INTRODUCTION IN GAVI-ELIGIBLE COUNTRIES. WITH OUR SUPPORT, THE GOVERNMENTS OF MALAWI AND NEPAL MADE THE DECISION TO INTRODUCE TCV AND SUCCESSFULLY APPLIED FOR ASSISTANCE FROM GAVI. PATH ALSO WORKED WITH THE GOVERNMENT OF KENYA ON ITS DECISION TO INTRODUCE TCV AND BEGIN PLANNING. TO ACCOUNT FOR CHALLENGES BROUGHT ON BY THE COVID-19 PANDEMIC, WE HELPED THE GOVERNMENTS OF LIBERIA, PAKISTAN, AND ZIMBABWE ADJUST THEIR TCV CAMPAIGNS.ALSO IN 2020, PATH CONTINUED TO COORDINATE A CONSORTIUM OF NINE INDEPENDENT RESEARCH INSTITUTIONS TO ANALYZE EVIDENCE ON SINGLE-DOSE HPV VACCINATION. FOR COUNTRIES WITH FINANCIAL, LOGISTICAL, OR OTHER BARRIERS TO INTRODUCTION, A SINGLE-DOSE REGIMEN COULD BE TRANSFORMATIVE. AMONG OTHER ASSISTANCE, OUR GLOBAL TEAM AND PARTNERS HELPED GAVI-ELIGIBLE COUNTRIES RESPOND TO THE COVID-19 PANDEMIC BY PIVOTING HPV VACCINATION PROGRAMS TO REACH OUT-OF-SCHOOL GIRLS.DRUG DEVELOPMENTTHROUGH OUR WORK ON DRUG DEVELOPMENT AND INTRODUCTION, PATH HELPS ENSURE THAT PEOPLE AROUND THE WORLD, ESPECIALLY CHILDREN IN LOW-RESOURCE SETTINGS, HAVE RELIABLE ACCESS TO LIFESAVING MEDICINES. OVER THE YEARS, OUR WORK HAS ADVANCED SOLUTIONS FOR A RANGE OF URGENT GLOBAL HEALTH CHALLENGES, INCLUDING ENTERIC AND DIARRHEAL DISEASES, NEGLECTED TROPICAL DISEASES, HIV/AIDS, AND MALARIA. DRAWING ON AN ENDURING COMMITMENT TO HEALTH EQUITY AND A UNIQUE PARTNERSHIP APPROACH THAT SPANS THE ACADEMIC, PRIVATE, NONPROFIT, AND GOVERNMENT SECTORS, OUR WORK OVERTURNS BARRIERS TO HEALTH AT EVERY STAGE OF DRUG DEVELOPMENT AND USE-FROM EARLY RESEARCH TO INTRODUCTION.IN 2020, WE COMPLETED A PHASE 2 PROOF-OF-CONCEPT CLINICAL TRIAL OF IOWH032, A NOVEL ANTISECRETORY DRUG CANDIDATE FOR THE TREATMENT OF CHOLERA. WHILE IOWH032 WAS NOT EFFICACIOUS IN THIS STUDY, WE LEARNED IMPORTANT LESSONS FOR FUTURE DRUG TRIALS AND CONTINUE TO EXPLORE OTHER USES OF THIS COMPOUND, INCLUDING FOR TREATMENT OF COVID-19, CYSTIC FIBROSIS, AND POTENTIALLY OTHER INDICATIONS.IN ADDITION, WE CONTINUED OUR WORK ON DEVELOPING NEW THERAPEUTICS FOR CRYPTOSPORIDIUM, A DEADLY DIARRHEA-CAUSING PARASITE FOR WHICH NO HIGHLY EFFECTIVE TREATMENT IS AVAILABLE. WE CONDUCTED KEY PRECLINICAL STUDIES AND SELECTED A COMPOUND FOR LARGE-ANIMAL EFFICACY TRIALS.THE DIARRHEA INNOVATIONS GROUP, AN INTERNATIONAL NETWORK OF CHILD HEALTH STAKEHOLDERS HOUSED WITHIN AND CO-CHAIRED BY PATH, CONTINUED TO ADVOCATE IN SUPPORT OF A LIFESAVING TREATMENT FOR DIARRHEA IN CHILDREN: THE USE OF CO-PACKAGED ORAL REHYDRATION SOLUTION AND ZINC, RECOGNIZED BY WHO AS AN ESSENTIAL MEDICINE. INCREASED ACCESS TO THIS TREATMENT COULD ACCELERATE PROGRESS TOWARD CHILD HEALTH GOALS.WITH OUR MANUFACTURING PARTNER QUANSYS BIOSCIENCES, WE MOVED TOWARD COMMERCIALIZATION OF A NEW TOOL FOR ASSESSING ENVIRONMENTAL ENTERIC DYSFUNCTION-AN INTESTINAL DISORDER RESPONSIBLE FOR A SIGNIFICANT PORTION OF THE GROWTH STUNTING OF APPROXIMATELY 140 MILLION CHILDREN WORLDWIDE.
4c
(Code:
) (Expenses $
32,223,655
including grants of $
7,574,230
) (Revenue $
)
TECHNOLOGY, ANALYTICS, AND MARKET INNOVATION: PATH'S TECHNOLOGY, ANALYTICS, AND MARKET INNOVATION (TAMI) DIVISION IS AN INTEGRATED GLOBAL PLATFORM FOR END-TO-END ADVANCEMENT OF HIGH-IMPACT MEDICAL DEVICES, HEALTH TECHNOLOGIES, DIAGNOSTICS, AND IN-COUNTRY "IMPACT LABS" THAT ADDRESS GLOBAL, REGIONAL, AND COUNTRY HEALTH NEEDS. TAMI ALSO MANAGES PATH'S WORK IN MARKET DYNAMICS AND DIGITAL AND DATA EXCELLENCE.(CONTINUED ON SCHEDULE O)MEDICAL DEVICES AND HEALTH TECHNOLOGIESTHE MEDICAL DEVICES AND HEALTH TECHNOLOGIES (MDHT) PROGRAM WITHIN TAMI IS PATH'S PRODUCT DEVELOPMENT ARM. THE PROGRAM WORKS WITH PUBLIC- AND PRIVATE-SECTOR PARTNERS AROUND THE WORLD TO DEVELOP, TEST, INTRODUCE, AND SCALE UP AFFORDABLE INNOVATIONS TO IMPROVE THE HEALTH OF PEOPLE IN LOW- AND MIDDLE-INCOME COUNTRIES.MILESTONES IN 2020 INCLUDED BEGINNING THE WORLD'S FIRST FREEZE-PREVENTIVE COLD BOX EVALUATION IN NEPAL; COMPLETING A THREE-YEAR INTRODUCTION AND SCALE-UP OF 7.1 PERCENT CHLORHEXIDINE FOR UMBILICAL CORD CARE IN FRANCOPHONE WEST AFRICA; RECEIVING REGULATORY APPROVAL IN GHANA AND KENYA FOR THE ELLAVI UTERINE BALLOON TAMPONADE-A PATH-DEVELOPED, LIFESAVING MEDICAL DEVICE FOR POSTPARTUM HEMORRHAGE; AND SERVING AS A KEY PARTNER ON THE GAVI-LED VACCINE INNOVATION PRIORITIZATION STRATEGY.MDHT ALSO ADDRESSED THE COVID-19 PANDEMIC: ONE EFFORT AIMED TO ACCELERATE EQUITABLE GLOBAL ACCESS TO COVID-19 VACCINES THROUGH A COLLABORATION WITH UNICEF AND THE COALITION FOR EPIDEMIC PREPAREDNESS INNOVATIONS. WORKING CLOSELY WITH PATH'S CENTER FOR VACCINE INNOVATION AND ACCESS, MDHT ASSESSED THE GLOBAL SUPPLY CHAIN FOR VACCINE COMPONENTS, VACCINE MANUFACTURING CAPACITY, SYRINGE AVAILABILITY, AND COLD CHAIN AND ULTRA-COLD CHAIN CAPACITY. WE ALSO ASSESSED COVID-19 VACCINE COLLATERAL MATERIALS AND INFORMATION-FOR EXAMPLE, NEW PACKAGING AND DELIVERY TECHNOLOGIES, WHO LABELING GUIDELINES, AND E-LEARNING MODULES.MDHT'S LIVING LABS INITIATIVE USED HUMAN-CENTERED DESIGN METHODS IN KENYA AND ZAMBIA TO IDENTIFY CHALLENGES AND PROPOSE SOLUTIONS TO THE MANY OBSTACLES IMMUNIZATION WORKERS FACE. IN KENYA, THE LIVING LABS TEAM ENGAGED HEALTH CARE WORKERS TO IDENTIFY CHALLENGES IN MANAGING POSTPARTUM HEMORRHAGE AND PRIORITIZE SOLUTIONS FOR GOVERNMENT RESPONSE. IN 2020, MDHT STAFF PRODUCED NINE PEER-REVIEWED JOURNAL ARTICLES AND RESEARCH REPORTS ON TOPICS RANGING FROM FREEZE-DRIED TABLETS FOR ORAL VACCINE DELIVERY TO CHLORHEXIDINE FOR FACILITY-BASED UMBILICAL CORD CARE.LAST, A CONSULTANT HIRED BY THE PATH SOUTH AFRICA IMPACT LAB WORKED CLOSELY WITH THE GLOBAL HEALTH INNOVATION ACCELERATOR/SOUTH AFRICAN MEDICAL RESEARCH COUNCIL ON A MEDICAL DEVICE LANDSCAPING ACTIVITY DESIGNED TO ACCELERATE PRODUCTION AND INTRODUCTION OF NOVEL HEALTH TECHNOLOGIES.DIAGNOSTICSPATH'S DIAGNOSTICS PROGRAM ADVANCES EQUITABLE AND SUSTAINABLE ACCESS TO AFFORDABLE, QUALITY-ASSURED DIAGNOSTICS FOR BETTER DIAGNOSIS AND TREATMENT IN LOW-RESOURCE SETTINGS.IN 2020, OUR PIONEERING WORK INCLUDED DEVELOPING, VALIDATING, EVALUATING, AND COMMERCIALIZING TESTS, REFERENCE ASSAYS, AND TOOLS; CONDUCTING LABORATORY PERFORMANCE EVALUATIONS AND CLINICAL STUDIES TO INFORM PATIENT CARE; FACILITATING A G6PD OPERATIONAL RESEARCH COMMUNITY OF PRACTICE; AND PUBLISHING 15 PEER-REVIEWED JOURNAL ARTICLES.THE DIAGNOSTICS TEAM RAPIDLY RESPONDED TO THE GLOBAL COVID-19 PANDEMIC WITH LABORATORY-BASED ACTIVITIES TO SUPPORT DIAGNOSTIC DEVELOPERS. THIS INCLUDED CREATING A BIOREPOSITORY OF QUALIFIED COVID-19 CLINICAL SAMPLES TO ACCELERATE THE DEVELOPMENT AND VALIDATION OF NEW COVID-19 DIAGNOSTIC TESTS (PROVIDED FREE OF CHARGE TO DEVELOPERS INTENDING TO SUPPLY GLOBAL MARKETS); CREATING FIVE DIGITAL, INTERACTIVE COVID-19 DIAGNOSTICS DASHBOARDS THAT AGGREGATE AND VISUALIZE PUBLICLY AVAILABLE INFORMATION ON THE DEVELOPMENT, SUPPLY, REGULATORY APPROVAL, AND PERFORMANCE OF COVID-19 DIAGNOSTIC TESTS (TO SUPPORT PRODUCT SELECTION AND PROCUREMENT DECISIONS WORLDWIDE); CONDUCTING IN-HOUSE EVALUATIONS OF NEW COMMERCIAL RAPID DIAGNOSTIC TESTS TO VERIFY PERFORMANCE CLAIMS AND FIT-FOR-PURPOSE IN INTERNATIONAL SETTINGS; ENSURING THE QUALITY OF COVID-19 RAPID DIAGNOSTIC TESTS WITH A BENCHMARKING PANEL THAT ENABLES UNBIASED, COMPARATIVE EVALUATIONS BETWEEN COVID-19 TESTS; SUPPORTING THE NATIONAL RESPONSE IN INDONESIA, MALAWI, NEPAL, AND PAKISTAN WITH ENVIRONMENTAL SURVEILLANCE DATA COLLECTION PROJECTS TO DETECT AND QUANTIFY THE PRESENCE OF SARS-COV-2 IN IMPACTED WASTEWATER; AND ENSURING THAT COVID-19 POINT-OF-CARE TESTS ARE SUITABLE FOR CLINICAL AND OPERATIONAL STUDIES IN BRAZIL.IN PARTNERSHIP WITH THE UNIVERSITY OF QUEENSLAND, THE DIAGNOSTICS TEAM SUPPORTED THE COMMERCIALIZATION OF CUSTOM MALARIA PROTEINS TO FACILITATE PERFORMANCE BENCHMARKING OF RAPID, ACCURATE, AND SPECIES-SPECIFIC MALARIA DIAGNOSTIC TESTS.THE TEAM ALSO SUBMITTED REGULATORY DOSSIERS FOR THE SD BIOSENSOR STANDARD G6PD TEST, WHICH GUIDES THE TREATMENT OF PLASMODIUM VIVAX MALARIA, TO THE AUSTRALIAN THERAPEUTIC GOODS ADMINISTRATION, THE US FOOD AND DRUG ADMINISTRATION, AND WHO FOR PREQUALIFICATION. IN 2020, NEARLY 75,000 OF THESE TESTS WERE DISTRIBUTED TO 30 COUNTRIES.INDIA IMPACT LABINDIA HAS A RICH INNOVATION ECOSYSTEM WITH UNIVERSITIES, PRIVATE-SECTOR FIRMS, AND A GROWING NUMBER OF ENTREPRENEURS FOCUSED ON DEVELOPING PRODUCTS AND SERVICES THAT MAKE HEALTH CARE MORE AFFORDABLE, ACCESSIBLE, AND EFFECTIVE. PATH'S INDIA IMPACT LAB, A PARTNERSHIP WITH TATA TRUSTS AND THE INDIAN INSTITUTE OF TECHNOLOGY DELHI, IS A PLATFORM TO ENABLE LATE-STAGE MEDICAL TECHNOLOGY INNOVATIONS TO ACHIEVE MARKET ENTRY, ADOPTION, AND SCALE. THE IMPACT LAB PARTNERS WITH TOP INDIAN TECHNOLOGY AND BUSINESS INCUBATORS IN THE LIFE SCIENCE AND HEALTH CARE INDUSTRIES. IN 2020, THE IMPACT LAB LED PATH'S PARTNERSHIP WITH THE CENTRE FOR CELLULAR AND MOLECULAR PLATFORMS, A PUBLIC-PRIVATE INITIATIVE THAT LAUNCHED THE COVID-19 INNOVATIONS DEPLOYMENT ACCELERATOR (C-CIDA) IN MARCH 2020. C-CIDA HELPS FAST-TRACK INNOVATIONS IN SCREENING, DIAGNOSIS, TREATMENT, MONITORING, CARE, AND MANAGEMENT OF COVID-19. THE IMPACT LAB CONTINUED TO SUPPORT THE MARKET ACCESS PROGRAM OF THE INDIA NATIONAL HEALTH AUTHORITY AND PARTNERED WITH XYNTEO INDIA ON PROJECT TEJ, AN INITIATIVE OF THE TELANGANA STATE GOVERNMENT AND MEDTECH CONNECT TO ACCELERATE INDIAN MEDICAL TECHNOLOGY INNOVATIONS. IN ADDITION, THE IMPACT LAB MANAGED A PIPELINE OF INNOVATIONS BEING EXPLORED FOR INTEGRATION WITH PRIMARY HEALTH CARE, IMMUNIZATION, NUTRITION, TB, COVID-19, FAMILY PLANNING, AND REPRODUCTIVE, MATERNAL, NEWBORN, CHILD, AND ADOLESCENT HEALTH PROGRAMS.THE IMPACT LAB ALSO CONTINUED ITS CROSSCUTTING SUPPORT OF VARIOUS PROGRAMS AT PATH; FOR EXAMPLE, EVALUATING LOW-FIELD MAGNETIC RESONANCE IMAGING, IMPROVING ACCESS TO COVID-19 TESTING IN INDIA THROUGH SYSTEM STRENGTHENING, EVALUATING A BLOW-FILL-SEAL ORAL VACCINE RECONSTITUTION DELIVERY SYSTEM, AND MARKET RESEARCH FOR NEWBORN SCREENING AND G6PD TESTING IN THE PRIVATE HEALTH SECTOR. MARKET DYNAMICSPATH'S MARKET DYNAMICS PROGRAM WORKS TO IMPROVE HEALTH EQUITY AND HEALTH OUTCOMES BY EVALUATING MARKETS, ASSESSING ROOT CAUSES OF LIMITED ACCESS TO HEALTH CARE PRODUCTS AND SERVICES, AND DESIGNING AND IMPLEMENTING MARKET-BASED INTERVENTIONS TO INCREASE ACCESS. THIS WORK COMPLEMENTS PATH'S OTHER EFFORTS, SUCH AS PRODUCT DEVELOPMENT/INTRODUCTION AND HEALTH SYSTEMS STRENGTHENING AND IS DONE IN CLOSE COLLABORATION WITH NATIONAL MINISTRIES OF HEALTH, GLOBAL AGENCIES, COMMERCIAL PARTNERS, AND PATH'S COUNTRY PROGRAMS.IN 2020, OUR WORK WAS FOCUSED PRIMARILY ON IMPROVING ACCESS TO MEDICAL OXYGEN AND RELATED RESPIRATORY CARE PRODUCTS FOR COVID-19 TREATMENT AS WELL AS MALARIA DRUGS AND DIAGNOSTICS.CENTER OF DIGITAL AND DATA EXCELLENCEPATH USES DIGITAL TECHNOLOGIES AND DATA-LED ACTION TO ADVANCE HEALTH EQUITY. IN 2020, PATH'S CENTER OF DIGITAL AND DATA EXCELLENCE (CODE) APPLIED ITS EXPERTISE TO ACCELERATE COUNTRY-LED DIGITAL HEALTH, DEEPEN THE USE OF DATA, AND SUPPORT THE GLOBAL COVID-19 RESPONSE. KEY ACCOMPLISHMENTS INCLUDED CO-AUTHORING WHO'S DIGITAL IMPLEMENTATION INVESTMENT GUIDE, WHICH OFFERS A SYSTEMIC PROCESS FOR COUNTRIES TO DEVELOP COSTED IMPLEMENTATION PLANS FOR DIGITAL HEALTH. DIGITAL SQUARE, A PATH-LED INITIATIVE, CONTINUED TO BRING DONORS AND PARTNERS TOGETHER TO IMPROVE HOW THE GLOBAL COMMUNITY DESIGNS, USES, AND PAYS FOR DIGITAL HEALTH TOOLS AND APPROACHES. DIGITAL SQUARE LED THE HEALTH DATA SCIENCE EXCHANGE, AN EXPLORATORY EFFORT TO UNDERSTAND HOW THE GREATER COORDINATION OF DATA SCIENCE TOOLS AND APPROACHES COULD IMPROVE HEALTH IMPACT. DIGITAL SQUARE ALSO BEGAN WORK ON MAP & MATCH, A LANDSCAPING ACTIVITY TO IDENTIFY EXISTING NATIONAL-LEVEL SOFTWARE TOOLS AND TECHNOLOGIES THAT CAN BE ADAPTED FOR COVID-19 RESPONSE.
(Code:
) (Expenses $
23,015,170
including grants of $
5,154,512
) (Revenue $
)
ADVOCACY AND PUBLIC POLICYPATH'S ADVOCACY AND PUBLIC POLICY TEAM WORKS IN THE UNITED STATES, AT THE GLOBAL LEVEL WITH MULTILATERAL AGENCIES, AND IN COUNTRIES AND COMMUNITIES AROUND THE WORLD. WE HELP POLICYMAKERS UNDERSTAND ISSUES AND MOTIVATE THEM TO COMMIT FUNDING, CRAFT POLICIES, AND SPONSOR INITIATIVES TO STRENGTHEN GLOBAL HEALTH. IN 2020, PATH LED EFFORTS TO ENSURE SUPPORT AMONG POLICYMAKERS IN THE UNITED STATES, EUROPE, AND MULTILATERAL AGENCIES TO MAINTAIN AND STRENGTHEN WORK IN RESEARCH AND DEVELOPMENT, MATERNAL AND CHILD HEALTH, IMMUNIZATION, AND PANDEMIC PREPAREDNESS AND RESPONSE. SUCCESSES INCLUDED PROTECTING KEY US GOVERNMENT FUNDING FOR PATH'S PRIORITY HEALTH AREAS, ENSURING US RE-INVESTMENT IN THE NEXT PHASE OF GAVI, AND HELPING DECISION-MAKERS CRAFT EMERGENCY FUNDING FOR THE GLOBAL RESPONSE TO COVID-19. WORKING WITH PARTNERS IN AFRICA, WE HELPED ADVANCE POLICIES TO IMPROVE THE HEALTH OF WOMEN AND CHILDREN AND PROTECT ESSENTIAL HEALTH SERVICES AS THE COVID-19 PANDEMIC TOOK AN UNPRECEDENTED TOLL ON HEALTH SYSTEMS; FOR EXAMPLE, IN KENYA, OUR ADVOCACY RESULTED IN ESTABLISHMENT OF THE GLOBAL FINANCING FACILITY'S MULTI-STAKEHOLDER COUNTRY PLATFORM, WHICH GIVES CIVIL SOCIETY A VOICE IN GOVERNMENT FUNDING OF MATERNAL AND CHILD HEALTH PROGRAMS. IN SOUTH AFRICA, WE SUPPORTED THE COUNTRY'S HEALTH REGULATORY AGENCY AS IT STREAMLINED AND DISSEMINATED INFORMATION ABOUT THE APPROVAL PIPELINE FOR COVID-19 TOOLS AND TREATMENTS. IN UGANDA, WE SUCCESSFULLY ADVOCATED FOR INCREASED FUNDING FOR PRIMARY HEALTH CARE AND SUPPORTED THE NATIONAL IMMUNIZATION PROGRAM IN DEVELOPING A PLAN TO ROLL OUT COVID-19 VACCINATION AND CATCH UP ON MISSED IMMUNIZATIONS DURING THE PANDEMIC. AND IN THE DRC, WE SUCCESSFULLY ADVOCATED FOR FULL DISBURSEMENT OF THE GOVERNMENT'S CO-FINANCING COMMITMENTS TO GAVI AS WELL AS ADDITIONAL FUNDS FOR IMMUNIZATION IN THREE PROVINCES.SPECIAL INITIATIVESPATH IS ENGAGED IN A VARIETY OF SPECIAL INITIATIVES THAT GALVANIZE OUR EXPERTISE AND RESOURCES AND THOSE OF OUR GLOBAL PARTNERS TO SAVE MORE LIVES, MORE QUICKLY. BY THE END OF 2020, WE HAD ACTIVE HEALTH IMPACT TEAMS IN SEVEN HEALTH AREAS. EACH HEALTH IMPACT TEAM HAS BEEN ONGOING FOR AT LEAST THREE YEARS, WORKING TO BUILD STRUCTURED COLLABORATION ACROSS PROGRAMS AND GEOGRAPHIES TO INCREASE PATH'S IMPACT.
4d
Other program services (Describe in Schedule O.)
(Expenses $
23,015,170
including grants of $
5,154,512
) (Revenue $
)
4e
Total program service expenses
262,890,896
Form
990
(2020)
Form 990 (2020)
Page
3
Part IV
Checklist of Required Schedules
Yes
No
1
Is the organization described in section 501(c)(3) or 4947(a)(1) (other than a private foundation)?
If "Yes," complete Schedule A
.....................
1
Yes
2
Is the organization required to complete
Schedule B, Schedule of Contributors
(see instructions)?
...
2
Yes
3
Did the organization engage in direct or indirect political campaign activities on behalf of or in opposition to candidates for public office?
If "Yes," complete Schedule C,
Part I
.............
3
No
4
Section 501(c)(3) organizations.
Did the organization engage in lobbying activities, or have a section 501(h) election in effect during the tax year?
If "Yes," complete Schedule C,
Part II
.........
4
Yes
5
Is the organization a section 501(c)(4), 501(c)(5), or 501(c)(6) organization that receives membership dues, assessments, or similar amounts as defined in Revenue Procedure 98-19?
If "Yes," complete Schedule C,
Part III
..
5
No
6
Did the organization maintain any donor advised funds or any similar funds or accounts for which donors have the right to provide advice on the distribution or investment of amounts in such funds or accounts?
If "Yes," complete
Schedule D,
Part I
.........................
6
No
7
Did the organization receive or hold a conservation easement, including easements to preserve open space,
the environment, historic land areas, or historic structures?
If "Yes," complete Schedule D,
Part II
....
7
No
8
Did the organization maintain collections of works of art, historical treasures, or other similar assets?
If "Yes,"
complete Schedule D,
Part III
..............
8
No
9
Did the organization report an amount in
Part X
, line 21 for escrow or custodial account liability; serve as a custodian for amounts not listed in
Part X
; or provide credit counseling, debt management, credit repair, or debt negotiation services?
If "Yes," complete Schedule D,
Part IV
..............
9
No
10
Did the organization, directly or through a related organization, hold assets in temporarily restricted endowments, permanent endowments, or quasi endowments?
If "Yes," complete Schedule D,
Part V
......
10
Yes
11
If the organization’s answer to any of the following questions is "Yes," then complete Schedule D, Parts VI, VII, VIII, IX, or X as applicable.
a
Did the organization report an amount for land, buildings, and equipment in
Part X
, line 10?
If "Yes," complete
Schedule D,
Part VI
.
...................
11a
Yes
b
Did the organization report an amount for investments—other securities in
Part X
, line 12 that is 5% or more of its total assets reported in
Part X
, line 16?
If "Yes," complete Schedule D,
Part VII
.......
11b
No
c
Did the organization report an amount for investments—program related in
Part X
, line 13 that is 5% or more of its total assets reported in
Part X
, line 16?
If "Yes," complete Schedule D,
Part VIII
.......
11c
No
d
Did the organization report an amount for other assets in
Part X
, line 15 that is 5% or more of its total assets reported in
Part X
, line 16?
If "Yes," complete Schedule D,
Part IX
............
11d
No
e
Did the organization report an amount for other liabilities in
Part X
, line 25?
If "Yes," complete Schedule D,
Part X
11e
No
f
Did the organization’s separate or consolidated financial statements for the tax year include a footnote that addresses the organization’s liability for uncertain tax positions under FIN 48 (ASC 740)?
If "Yes," complete Schedule D,
Part X
11f
No
12a
Did the organization obtain separate, independent audited financial statements for the tax year?
If "Yes," complete
Schedule D, Parts XI and XII
......................
12a
No
b
Was the organization included in consolidated, independent audited financial statements for the tax year?
If "Yes," and if the organization answered "No" to line 12a, then completing Schedule D, Parts XI and XII is optional
12b
Yes
13
Is the organization a school described in section 170(b)(1)(A)(ii)?
If "Yes," complete Schedule E
13
No
14a
Did the organization maintain an office, employees, or agents outside of the United States?
.....
14a
Yes
b
Did the organization have aggregate revenues or expenses of more than $10,000 from grantmaking, fundraising, business, investment, and program service activities outside the United States, or aggregate foreign investments valued at $100,000 or more?
If "Yes," complete Schedule F, Parts I and IV
.........
14b
Yes
15
Did the organization report on
Part IX
, column (A), line 3, more than $5,000 of grants or other assistance to or for any foreign organization?
If “Yes,” complete Schedule F, Parts II and IV
.....
15
Yes
16
Did the organization report on
Part IX
, column (A), line 3, more than $5,000 of aggregate grants or other assistance to or for foreign individuals?
If “Yes,” complete Schedule F, Parts III and IV
...
16
No
17
Did the organization report a total of more than $15,000 of expenses for professional fundraising services on
Part IX
, column (A), lines 6 and 11e?
If "Yes," complete Schedule G,
Part I
(see instructions)
....
17
No
18
Did the organization report more than $15,000 total of fundraising event gross income and contributions on
Part VIII
, lines 1c and 8a?
If "Yes," complete Schedule G,
Part II
............
18
No
19
Did the organization report more than $15,000 of gross income from gaming activities on
Part VIII
, line 9a?
If "Yes," complete Schedule G,
Part III
...................
19
No
20a
Did the organization operate one or more hospital facilities?
If "Yes," complete Schedule H
....
20a
No
b
If "Yes" to line 20a, did the organization attach a copy of its audited financial statements to this return?
20b
21
Did the organization report more than $5,000 of grants or other assistance to any domestic organization or domestic government on
Part IX
, column (A), line 1?
If “Yes,” complete Schedule I, Parts I and II
.....
21
Yes
Form
990
(2020)
Form 990 (2020)
Page
4
Part IV
Checklist of Required Schedules
(continued)
Yes
No
22
Did the organization report more than $5,000 of grants or other assistance to or for domestic individuals on
Part IX
, column (A), line 2?
If “Yes,” complete Schedule I, Parts I and III
........
22
No
23
Did the organization answer "Yes" to
Part VII
, Section A, line 3, 4, or 5 about compensation of the organization’s current and former officers, directors, trustees, key employees, and highest compensated employees?
If "Yes," complete Schedule J
.......................
23
Yes
24a
Did the organization have a tax-exempt bond issue with an outstanding principal amount of more than $100,000 as of the last day of the year, that was issued after December 31, 2002?
If “Yes,” answer lines 24b through 24d and complete Schedule K. If “No,” go to line 25a
...............
24a
No
b
Did the organization invest any proceeds of tax-exempt bonds beyond a temporary period exception?
...
24b
c
Did the organization maintain an escrow account other than a refunding escrow at any time during the year
to defease any tax-exempt bonds?
...............
24c
d
Did the organization act as an "on behalf of" issuer for bonds outstanding at any time during the year?
...
24d
25a
Section 501(c)(3), 501(c)(4), and 501(c)(29) organizations.
Did the organization engage in an excess benefit transaction with a disqualified person during the year?
If "Yes," complete Schedule L,
Part I
....
25a
No
b
Is the organization aware that it engaged in an excess benefit transaction with a disqualified person in a prior year, and that the transaction has not been reported on any of the organization’s prior Forms 990 or 990-EZ?
If "Yes," complete Schedule L,
Part I
.......................
25b
No
26
Did the organization report any amount on Part X, line 5 or 22 for receivables from or payables to any current or former officer, director, trustee, key employee, creator or founder, substantial contributor, or 35% controlled entity or family member of any of these persons?
If "Yes," complete Schedule L,
Part II
...........
26
No
27
Did the organization provide a grant or other assistance to any current or former officer, director, trustee, key employee, creator or founder, substantial contributor, or employee thereof, a grant selection committee member, or to a 35% controlled entity (including an employee thereof) or family member of any of these persons?
If "Yes," complete
Schedule L,
Part III
.........................
27
No
28
Was the organization a party to a business transaction with one of the following parties (see Schedule L,
Part IV
instructions for applicable filing thresholds, conditions, and exceptions):
a
A current or former officer, director, trustee, key employee, creator or founder, or substantial contributor?
If "Yes," complete Schedule L,
Part IV
......................
28a
No
b
A family member of any individual described in line 28a?
If "Yes," complete Schedule L,
Part IV
.....
28b
No
c
A 35% controlled entity of one or more individuals and/or organizations described in lines 28a or 28b?
If "Yes," complete Schedule L,
Part IV
.....................
28c
No
29
Did the organization receive more than $25,000 in non-cash contributions?
If "Yes," complete Schedule M
..
29
Yes
30
Did the organization receive contributions of art, historical treasures, or other similar assets, or qualified conservation contributions?
If "Yes," complete Schedule M
.................
30
No
31
Did the organization liquidate, terminate, or dissolve and cease operations?
If "Yes," complete Schedule N,
Part I
31
No
32
Did the organization sell, exchange, dispose of, or transfer more than 25% of its net assets?
If "Yes," complete Schedule N,
Part II
........................
32
No
33
Did the organization own 100% of an entity disregarded as separate from the organization under Regulations sections 301.7701-2 and 301.7701-3?
If "Yes," complete Schedule R,
Part I
............
33
No
34
Was the organization related to any tax-exempt or taxable entity?
If "Yes," complete Schedule R,
Part II
, III, or IV, and
Part V
, line 1
.........................
34
Yes
35a
Did the organization have a controlled entity within the meaning of section 512(b)(13)?
35a
Yes
b
If ‘Yes’ to line 35a, did the organization receive any payment from or engage in any transaction with a controlled entity within the meaning of section 512(b)(13)?
If "Yes," complete Schedule R,
Part V
, line 2
...
35b
Yes
36
Section 501(c)(3) organizations.
Did the organization make any transfers to an exempt non-charitable related organization?
If "Yes," complete Schedule R,
Part V
, line 2
.............
36
No
37
Did the organization conduct more than 5% of its activities through an entity that is not a related organization and that is treated as a partnership for federal income tax purposes?
If "Yes," complete Schedule R,
Part VI
37
No
38
Did the organization complete Schedule O and provide explanations in Schedule O for
Part VI
, lines 11b and 19?
Note.
All Form 990 filers are required to complete Schedule O.
............
38
Yes
Part V
Statements Regarding Other IRS Filings and Tax Compliance
Check if Schedule O contains a response or note to any line in this
Part V
...........
Yes
No
1a
Enter the number reported in Box 3 of Form 1096. Enter -0- if not applicable
..
1a
221
b
Enter the number of Forms W-2G included in line 1a. Enter -0- if not applicable
.
1b
0
c
Did the organization comply with backup withholding rules for reportable payments to vendors and reportable gaming (gambling) winnings to prize winners?
..................
1c
Yes
Form
990
(2020)
Form 990 (2020)
Page
5
Part V
Statements Regarding Other IRS Filings and Tax Compliance
(continued)
2a
Enter the number of employees reported on Form W-3, Transmittal of Wage and
Tax Statements, filed for the calendar year ending with or within the year covered by this return
..................
2a
714
b
If at least one is reported on line 2a, did the organization file all required federal employment tax returns?
Note.
If the sum of lines 1a and 2a is greater than 250, you may be required to e-file (see instructions)
2b
Yes
3a
Did the organization have unrelated business gross income of $1,000 or more during the year?
...
3a
No
b
If “Yes,” has it filed a Form 990-T for this year?
If “No” to line 3b, provide an explanation in Schedule O
...
3b
4a
At any time during the calendar year, did the organization have an interest in, or a signature or other authority over, a financial account in a foreign country (such as a bank account, securities account, or other financial account)?
..
4a
Yes
b
If "Yes," enter the name of the foreign country:
BE
,
CH
,
ET
,
GH
,
IN
,
KE
,
MZ
,
PE
,
SG
,
SZ
,
TZ
,
UG
,
UK
,
VM
,
ZA
,
CG
,
MI
,
BM
,
SF
,
UP
See instructions for filing requirements for FinCEN Form 114, Report of Foreign Bank and Financial Accounts (FBAR).
5a
Was the organization a party to a prohibited tax shelter transaction at any time during the tax year?
..
5a
No
b
Did any taxable party notify the organization that it was or is a party to a prohibited tax shelter transaction?
5b
No
c
If "Yes," to line 5a or 5b, did the organization file Form 8886-T?
............
5c
6a
Does the organization have annual gross receipts that are normally greater than $100,000, and did the organization solicit any contributions that were not tax deductible as charitable contributions?
...
6a
No
b
If "Yes," did the organization include with every solicitation an express statement that such contributions or gifts were not tax deductible?
......................
6b
7
Organizations that may receive deductible contributions under section 170(c).
a
Did the organization receive a payment in excess of $75 made partly as a contribution and partly for goods and services provided to the payor?
....................
7a
No
b
If "Yes," did the organization notify the donor of the value of the goods or services provided?
.....
7b
c
Did the organization sell, exchange, or otherwise dispose of tangible personal property for which it was required to file Form 8282?
.........................
7c
No
d
If "Yes," indicate the number of Forms 8282 filed during the year
....
7d
e
Did the organization receive any funds, directly or indirectly, to pay premiums on a personal benefit contract?
7e
No
f
Did the organization, during the year, pay premiums, directly or indirectly, on a personal benefit contract?
..
7f
No
g
If the organization received a contribution of qualified intellectual property, did the organization file Form 8899 as required?
......................
7g
h
If the organization received a contribution of cars, boats, airplanes, or other vehicles, did the organization file a Form 1098-C?
..........................
7h
8
Sponsoring organizations maintaining donor advised funds.
Did a donor advised fund maintained by the sponsoring organization have excess business holdings at any time during the year?
........
8
9
Sponsoring organizations maintaining donor advised funds.
a
Did the sponsoring organization make any taxable distributions under section 4966?
........
9a
b
Did the sponsoring organization make a distribution to a donor, donor advisor, or related person?
...
9b
10
Section 501(c)(7) organizations.
Enter:
a
Initiation fees and capital contributions included on
Part VIII
, line 12
...
10a
b
Gross receipts, included on Form 990,
Part VIII
, line 12, for public use of club facilities
10b
11
Section 501(c)(12) organizations.
Enter:
a
Gross income from members or shareholders
.........
11a
b
Gross income from other sources (Do not net amounts due or paid to other sources against amounts due or received from them.)
..........
11b
12a
Section 4947(a)(1) non-exempt charitable trusts.
Is the organization filing Form 990 in lieu of Form 1041?
12a
b
If "Yes," enter the amount of tax-exempt interest received or accrued during the year.
12b
13
Section 501(c)(29) qualified nonprofit health insurance issuers.
a
Is the organization licensed to issue qualified health plans in more than one state?
.........
Note.
See the instructions for additional information the organization must report on Schedule O.
13a
b
Enter the amount of reserves the organization is required to maintain by the states in which the organization is licensed to issue qualified health plans
....
13b
c
Enter the amount of reserves on hand
............
13c
14a
Did the organization receive any payments for indoor tanning services during the tax year?
.....
14a
No
b
If "Yes," has it filed a Form 720 to report these payments?
If "No," provide an explanation in Schedule O
..
14b
15
Is the organization subject to the section 4960 tax on payment(s) of more than $1,000,000 in remuneration or excess parachute payment(s) during the year?
....................
If "Yes," see instructions and file Form 4720, Schedule N.
15
No
16
Is the organization an educational institution subject to the section 4968 excise tax on net investment income?
..
If "Yes," complete Form 4720, Schedule O.
16
No
Form
990
(2020)
Form 990 (2020)
Page
6
Part VI
Governance, Management, and Disclosure
For each "Yes" response to lines 2 through 7b below, and for a "No" response to lines
8a, 8b, or 10b below, describe the circumstances, processes, or changes in Schedule O. See instructions.
Check if Schedule O contains a response or note to any line in this
Part VI
..............
Section A. Governing Body and Management
Yes
No
1a
Enter the number of voting members of the governing body at the end of the tax year
1a
15
If there are material differences in voting rights among members of the governing body, or if the governing body delegated broad authority to an executive committee or similar committee, explain in Schedule O.
b
Enter the number of voting members included in line 1a, above, who are independent
1b
15
2
Did any officer, director, trustee, or key employee have a family relationship or a business relationship with any other officer, director, trustee, or key employee?
.................
2
No
3
Did the organization delegate control over management duties customarily performed by or under the direct supervision of officers, directors or trustees, or key employees to a management company or other person?
.
3
No
4
Did the organization make any significant changes to its governing documents since the prior Form 990 was filed?
.
4
No
5
Did the organization become aware during the year of a significant diversion of the organization’s assets?
.
5
No
6
Did the organization have members or stockholders?
................
6
No
7a
Did the organization have members, stockholders, or other persons who had the power to elect or appoint one or more members of the governing body?
....................
7a
No
b
Are any governance decisions of the organization reserved to (or subject to approval by) members, stockholders, or persons other than the governing body?
...................
7b
No
8
Did the organization contemporaneously document the meetings held or written actions undertaken during the year by the following:
a
The governing body?
.......................
8a
Yes
b
Each committee with authority to act on behalf of the governing body?
............
8b
Yes
9
Is there any officer, director, trustee, or key employee listed in
Part VII
, Section A, who cannot be reached at the organization’s mailing address?
If "Yes," provide the names and addresses in Schedule O
.......
9
No
Section B. Policies
(
This Section B requests information about policies not required by the Internal Revenue Code.
)
Yes
No
10a
Did the organization have local chapters, branches, or affiliates?
............
10a
No
b
If "Yes," did the organization have written policies and procedures governing the activities of such chapters, affiliates, and branches to ensure their operations are consistent with the organization's exempt purposes?
10b
11a
Has the organization provided a complete copy of this Form 990 to all members of its governing body before filing the form?
............................
11a
Yes
b
Describe in Schedule O the process, if any, used by the organization to review this Form 990.
.....
12a
Did the organization have a written conflict of interest policy?
If "No," go to line 13
.......
12a
Yes
b
Were officers, directors, or trustees, and key employees required to disclose annually interests that could give rise to conflicts?
..........................
12b
Yes
c
Did the organization regularly and consistently monitor and enforce compliance with the policy?
If "Yes," describe in Schedule O how this was done
...................
12c
Yes
13
Did the organization have a written whistleblower policy?
...............
13
Yes
14
Did the organization have a written document retention and destruction policy?
.........
14
Yes
15
Did the process for determining compensation of the following persons include a review and approval by independent persons, comparability data, and contemporaneous substantiation of the deliberation and decision?
a
The organization’s CEO, Executive Director, or top management official
...........
15a
Yes
b
Other officers or key employees of the organization
................
15b
Yes
If "Yes" to line 15a or 15b, describe the process in Schedule O (see instructions).
16a
Did the organization invest in, contribute assets to, or participate in a joint venture or similar arrangement with a taxable entity during the year?
......................
16a
No
b
If "Yes," did the organization follow a written policy or procedure requiring the organization to evaluate its participation in joint venture arrangements under applicable federal tax law, and take steps to safeguard the organization’s exempt status with respect to such arrangements?
............
16b
Section C. Disclosure
17
List the states with which a copy of this Form 990 is required to be filed
AL
,
AR
,
CA
,
CT
,
FL
,
IL
,
KS
,
KY
,
MA
,
MD
,
MI
,
MN
,
MS
,
NC
,
NH
,
NJ
,
NM
,
NY
,
OK
,
OR
,
PA
,
RI
,
SC
,
TN
,
UT
,
VA
,
WI
,
WV
18
Section 6104 requires an organization to make its Form 1023 (or 1024-A if applicable), 990, and 990-T (501(c)(3)s only) available for public inspection. Indicate how you made these available. Check all that apply.
Own website
Another's website
Upon request
Other (explain in Schedule O)
19
Describe in Schedule O whether (and if so, how) the organization made its governing documents, conflict of interest policy, and financial statements available to the public during the tax year.
20
State the name, address, and telephone number of the person who possesses the organization's books and records:
KELLY PRIESTLEY CONTROLLER
2201 WESTLAKE AVE SUITE 200
SEATTLE
,
WA
98121
(206) 285-3500
Form
990
(2020)
Form 990 (2020)
Page
7
Part VII
Compensation of Officers, Directors,Trustees, Key Employees, Highest Compensated Employees, and Independent Contractors
Check if Schedule O contains a response or note to any line in this
Part VII
..............
Section A. Officers, Directors, Trustees, Key Employees, and Highest Compensated Employees
1a
Complete this table for all persons required to be listed. Report compensation for the calendar year ending with or within the organization’s tax year.
List all of the organization’s
current
officers, directors, trustees (whether individuals or organizations), regardless of amount
of compensation. Enter -0- in columns (D), (E), and (F) if no compensation was paid.
List all of the organization’s
current
key employees, if any. See instructions for definition of "key employee."
List the organization’s five
current
highest compensated employees (other than an officer, director, trustee or key employee)
who received reportable compensation (Box 5 of Form W-2 and/or Box 7 of Form 1099-MISC) of more than $100,000 from the
organization and any related organizations.
List all of the organization’s
former
officers, key employees, or highest compensated employees who received more than $100,000
of reportable compensation from the organization and any related organizations.
List all of the organization’s
former directors or trustees
that received, in the capacity as a former director or trustee of the
organization, more than $10,000 of reportable compensation from the organization and any related organizations.
See instructions for the order in which to list the persons above.
Check this box if neither the organization nor any related organization compensated any current officer, director, or trustee.
(A)
Name and title
(B)
Average hours per week (list any hours for related organizations below dotted line)
(C)
Position (do not check more than one box, unless person is both an officer and a director/trustee)
(D)
Reportable compensation from the organization (W-2/1099-MISC)
(E)
Reportable compensation from related organizations (W-2/1099-MISC)
(F)
Estimated amount of other compensation from the organization and related organizations
(1)
DAVID KING
......................................................................
CHAIR
2.00
.................
0.00
X
X
0
0
0
(2)
BETH GALETTI
......................................................................
VICE CHAIR
2.00
.................
0.00
X
X
0
0
0
(3)
YEHONG ZHANG
......................................................................
SECRETARY
2.00
.................
0.00
X
X
0
0
0
(4)
BRUCE MCNAMER
......................................................................
TREASURER
2.00
.................
0.00
X
X
0
0
0
(5)
FELIX OLALE
......................................................................
DIRECTOR
2.00
.................
0.00
X
0
0
0
(6)
JO ADDY
......................................................................
DIRECTOR
2.00
.................
0.00
X
0
0
0
(7)
IREENA VITTAL
......................................................................
DIRECTOR
2.00
.................
0.00
X
0
0
0
(8)
DEANNA OPPENHEIMER
......................................................................
DIRECTOR (BEGAN 6/2020)
2.00
.................
0.00
X
0
0
0
(9)
JOHN-ARNE ROTTINGEN
......................................................................
DIRECTOR
2.00
.................
0.00
X
0
0
0
(10)
JOEL HOLSINGER
......................................................................
DIRECTOR
2.00
.................
0.00
X
0
0
0
(11)
HELENA WAYTH
......................................................................
DIRECTOR
2.00
.................
0.00
X
0
0
0
(12)
SANFORD MELZER
......................................................................
DIRECTOR
2.00
.................
0.00
X
0
0
0
(13)
ABAYOMI SULE
......................................................................
DIRECTOR
2.00
.................
0.00
X
0
0
0
(14)
LISA ANDERSON
......................................................................
DIRECTOR
2.00
.................
0.00
X
0
0
0
(15)
RACHEL SIBANDE
......................................................................
DIRECTOR
2.00
.................
0.00
X
0
0
0
(16)
STEPHEN B DAVIS
......................................................................
PRESIDENT AND CEO (RESIGNED 1/2020)
39.00
.................
1.00
X
249,057
0
13,602
(17)
NIKOLAJ JESTED GILBERT
......................................................................
PRESIDENT AND CEO (FROM 1/2020)
39.00
.................
1.00
X
256,555
315,385
44,054
Form
990
(2020)
Form 990 (2020)
Page
8
Part VII
Section A. Officers, Directors, Trustees, Key Employees, and Highest Compensated Employees
(continued)
(A)
Name and title
(B)
Average hours per week (list any hours for related organizations below dotted line)
(C)
Position (do not check more than one box, unless person is both an officer and a director/trustee)
(D)
Reportable compensation from the organization (W-2/1099-MISC)
(E)
Reportable compensation from related organizations (W-2/1099-MISC)
(F)
Estimated amount of other compensation from the organization and related organizations
(18)
JERRY KUO
........................................................................
CHIEF OF STRATEGIC FINANCE
39.00
.......................
1.00
X
252,897
0
58,226
(19)
BRIAN N NEVILLE
........................................................................
CHIEF OF ACCOUNTING
39.00
.......................
1.00
X
260,514
0
36,826
(20)
PHILIPPE GUINOT
........................................................................
CHIEF OF BUSINESS, FIN. & OPS.
39.00
.......................
1.00
X
0
258,031
22,877
(21)
DAVID C KASLOW
........................................................................
VP - ESSENTIAL MEDICNES
39.00
.......................
1.00
X
427,937
0
69,391
(22)
JEFFREY D BERNSON
........................................................................
VP - TECH, ANALYTICS, MRKT INNOV.
40.00
.......................
0.00
X
322,741
0
57,193
(23)
DAVID W FLEMING
........................................................................
VP - PUBLIC HEALTH
40.00
.......................
0.00
X
364,555
0
44,832
(24)
ELAINE L GIBBONS
........................................................................
VP - GLOBAL ENGAGEMENT
39.00
.......................
1.00
X
291,278
0
76,724
(25)
MOLLI M BARNES
........................................................................
CHIEF PEOPLE OFFICER
40.00
.......................
0.00
X
278,509
0
52,067
(26)
ERICA JANE SESSLE
........................................................................
CHIEF OF STAFF
40.00
.......................
0.00
X
238,815
0
54,599
(27)
SABRINA L POWERS
........................................................................
GENERAL COUNSEL
40.00
.......................
0.00
X
232,450
0
37,202
(28)
TRAD M HATTON
........................................................................
COUNTRY DIRECTOR
40.00
.......................
0.00
X
376,676
0
54,537
(29)
JAMES B MCKENNA
........................................................................
DEPUTY DIRECTOR
40.00
.......................
0.00
X
321,745
0
84,937
(30)
ASHLEY J BIRKETT
........................................................................
GLOBAL HEAD, MALARIA VACCINES
40.00
.......................
0.00
X
346,772
0
56,185
(31)
BRUCE LAMONT INNIS
........................................................................
GLOBAL HEAD, RESPIRATORY INFECTIONS
40.00
.......................
0.00
X
357,737
0
32,603
(32)
JOHN O KONZ
........................................................................
GLOBAL HEAD, FINANCIAL MANAGEMENT
40.00
.......................
0.00
X
346,902
0
67,132
1b
Sub-Total
................
c
Total from continuation sheets to
Part VII
, Section A
....
d
Total (add lines 1b and 1c)
...........
4,925,140
573,416
862,987
2
Total number of individuals (including but not limited to those listed above) who received more than $100,000 of reportable compensation from the organization
373
Yes
No
3
Did the organization list any
former
officer, director or trustee, key employee, or highest compensated employee on line 1a?
If "Yes," complete Schedule J for such individual
..............
3
No
4
For any individual listed on line 1a, is the sum of reportable compensation and other compensation from the organization and related organizations greater than $150,000?
If "Yes," complete Schedule J for such
individual
...........................
4
Yes
5
Did any person listed on line 1a receive or accrue compensation from any unrelated organization or individual for services rendered to the organization?
If "Yes," complete Schedule J for such person
........
5
No
Section B. Independent Contractors
1
Complete this table for your five highest compensated independent contractors that received more than $100,000 of compensation from the organization. Report compensation for the calendar year ending with or within the organization’s tax year.
(A)
Name and business address
(B)
Description of services
(C)
Compensation
RANDSTAD INDIA PVT LTD
SUIT NO 001 002 COPIA
NEW DELHI
110025
IN
STAFFING SERVICES
996,065
SAFEGUARD WORLD INT'L
MOSS LANE EDWIN FODEN BUS CENTRE
SANDBACH
CW113AE
UK
GENERAL CONTRACTOR
890,294
WMBE PAYROLLING DBA TARGETCW
9475 CHESAPEAKE DR
SAN DIEGO
,
CA
92123
GENERAL CONTRACTOR
736,559
JAMES G DAVIS CONTRUCTION CORPORATION
12530 PARKLAND DRIVE
ROCKVILLE
,
MD
20852
GENERAL CONTRACTOR
622,327
INSTRUMENT LLC
3529 NORTH WILLIAMS AVENUE
PORTLAND
,
OR
97227
CONSULTING
488,228
2
Total number of independent contractors (including but not limited to those listed above) who received more than $100,000 of compensation from the organization
45
Form
990
(2020)
Form 990 (2020)
Page
9
Part VIII
Statement of Revenue
Check if Schedule O contains a response or note to any line in this
Part VIII
.............
(A)
Total revenue
(B)
Related or
exempt
function
revenue
(C)
Unrelated
business
revenue
(D)
Revenue
excluded from
tax under sections
512 - 514
1a
Federated campaigns
..
1a
b
Membership dues
..
1b
c
Fundraising events
..
1c
d
Related organizations
1d
4,386,562
e
Government grants (contributions)
1e
98,650,801
f
All other contributions, gifts, grants, and similar amounts not included above
1f
184,417,020
g
Noncash contributions included in lines 1a - 1f:$
1g
761,052
h Total.
Add lines 1a-1f
.......
287,454,383
Business Code
2a
b
c
d
e
f
All other program service revenue.
g
Total.
Add lines 2a–2f
.....
3
Investment income (including dividends, interest, and other
similar amounts)
......
12,207,084
12,207,084
4
Income from investment of tax-exempt bond proceeds
5
Royalties
...........
(ii) Personal
(i) Real
6a
Gross rents
6a
b
Less: rental expenses
6b
c
Rental income or (loss)
6c
d
Net rental income or (loss)
.......
(ii) Other
(i) Securities
7a
Gross amount from sales of assets other than inventory
21,954
57,083,069
7a
b
Less: cost or other basis and sales expenses
12,461
56,797,395
7b
c
Gain or (loss)
9,493
285,674
7c
d
Net gain or (loss)
.........
295,167
295,167
8a
Gross income from fundraising events (not including $
of contributions reported on line 1c).
See
Part IV
, line 18
....
8a
b
Less: direct expenses
...
8b
c
Net income or (loss) from fundraising events
..
9a
Gross income from gaming activities.
See
Part IV
, line 19
...
9a
b
Less: direct expenses
...
9b
c
Net income or (loss) from gaming activities
..
10a
Gross sales of inventory, less
returns and allowances
..
10a
b
Less: cost of goods sold
..
10b
c
Net income or (loss) from sales of inventory
..
Business Code
Miscellaneous Revenue
11a
REIMBURSEMENTS
900099
705,455
705,455
b
OTHER
900099
324,657
324,657
c
d
All other revenue
....
e
Total.
Add lines 11a–11d
......
1,030,112
12
Total revenue.
See instructions
.....
300,986,746
0
0
13,532,363
Form
990
(2020)
Form 990 (2020)
Page
10
Part IX
Statement of Functional Expenses
Section 501(c)(3) and 501(c)(4) organizations must complete all columns. All other organizations must complete column (A).
Check if Schedule O contains a response or note to any line in this
Part IX
..............
Do not include amounts reported on lines 6b,
7b, 8b, 9b, and 10b of
Part VIII
.
(A)
Total expenses
(B)
Program service
expenses
(C)
Management and
general expenses
(D)
Fundraising
expenses
1
Grants and other assistance to domestic organizations and domestic governments. See
Part IV
, line 21
....
19,808,249
19,808,249
2
Grants and other assistance to domestic individuals. See
Part IV
, line 22
...........
3
Grants and other assistance to foreign organizations, foreign governments, and foreign individuals. See
Part IV
, lines 15 and 16.
.............
48,186,578
48,186,578
4
Benefits paid to or for members
.......
5
Compensation of current officers, directors, trustees, and key employees
...........
3,696,147
443,030
3,230,480
22,637
6
Compensation not included above, to disqualified persons (as defined under section 4958(f)(1)) and persons described in section 4958(c)(3)(B)
.........
7
Other salaries and wages
........
95,455,775
89,233,434
4,839,226
1,383,115
8
Pension plan accruals and contributions (include section 401(k) and 403(b) employer contributions)
....
9,902,096
6,999,543
2,788,845
113,708
9
Other employee benefits
.......
16,637,172
13,244,535
3,259,730
132,907
10
Payroll taxes
...........
6,405,206
4,527,542
1,804,106
73,558
11
Fees for services (non-employees):
a
Management
......
b
Legal
.........
805,000
428,419
376,581
c
Accounting
...........
478,838
186,280
292,558
d
Lobbying
...........
1,845
1,845
e
Professional fundraising services.
See
Part IV
, line 17
f
Investment management fees
......
177,923
177,923
g
Other (If line 11g amount exceeds 10% of line 25, column (A) amount, list line 11g expenses on Schedule O)
15,387,022
12,189,851
3,136,788
60,383
12
Advertising and promotion
....
286,728
220,391
3,897
62,440
13
Office expenses
.......
7,780,893
6,665,971
1,027,428
87,494
14
Information technology
......
1,392,563
390,928
981,124
20,511
15
Royalties
..
337,136
337,136
16
Occupancy
...........
12,679,852
272,765
12,407,087
17
Travel
............
7,889,458
7,460,553
423,813
5,092
18
Payments of travel or entertainment expenses for any federal, state, or local public officials
.
19
Conferences, conventions, and meetings
....
5,292,304
5,113,342
174,332
4,630
20
Interest
...........
1,904
154
1,750
21
Payments to affiliates
.......
22
Depreciation, depletion, and amortization
..
3,101,076
12,403
3,088,673
23
Insurance
...
849,014
210,678
638,336
24
Other expenses. Itemize expenses not covered above (List miscellaneous expenses in line 24e. If line 24e amount exceeds 10% of line 25, column (A) amount, list line 24e expenses on Schedule O.)
a
SUBCONTRACTORS
26,935,850
26,932,945
2,905
b
EQUIP RENT & MAINT
6,595,821
5,287,573
1,303,962
4,286
c
DIRECT AID TO BENEFICIA
1,393,030
1,393,030
d
FACILITIES ALLOC
0
13,189,972
-13,402,840
212,868
e
All other expenses
1,582,003
153,749
1,201,997
226,257
25
Total functional expenses.
Add lines 1 through 24e
293,059,483
262,890,896
27,758,701
2,409,886
26
Joint costs.
Complete this line only if the organization reported in column (B) joint costs from a combined educational campaign and fundraising solicitation.
Check here
if following SOP 98-2 (ASC 958-720).
Form
990
(2020)
Form 990 (2020)
Page
11
Part X
Balance Sheet
Check if Schedule O contains a response or note to any line in this
Part IX
..............
(A)
Beginning of year
(B)
End of year
1
Cash–non-interest-bearing
........
8,845,877
1
7,194,550
2
Savings and temporary cash investments
.........
17,517,988
2
9,719,000
3
Pledges and grants receivable, net
......
44,215,907
3
39,742,632
4
Accounts receivable, net
.............
16,731,594
4
258,036
5
Loans and other receivables from any current or former officer, director, trustee, key employee, creator or founder, substantial contributor, or 35% controlled entity or family member of any of these persons
.......
5
6
Loans and other receivables from other disqualified persons (as defined under section 4958(f)(1)), and persons described in section 4958(c)(3)(B)
...
6
7
Notes and loans receivable, net
...........
7
8
Inventories for sale or use
............
8
9
Prepaid expenses and deferred charges
......
7,170,218
9
7,008,112
10a
Land, buildings, and equipment: cost or other basis. Complete
Part VI
of Schedule D
10a
38,112,788
b
Less: accumulated depreciation
10b
29,699,485
9,991,630
10c
8,413,303
11
Investments—publicly traded securities
.
138,590,941
11
211,220,570
12
Investments—other securities. See
Part IV
, line 11
.....
12
13
Investments—program-related. See
Part IV
, line 11
..
13
14
Intangible assets
...............
14
15
Other assets. See
Part IV
, line 11
...........
15
16
Total assets.
Add lines 1 through 15 (must equal line 33)
...
243,064,155
16
283,556,203
17
Accounts payable and accrued expenses
.....
204,045,574
17
234,982,056
18
Grants payable
...
18
19
Deferred revenue
.........
19
20
Tax-exempt bond liabilities
.........
20
21
Escrow or custodial account liability.
Complete
Part IV
of Schedule D
21
22
Loans and other payables to any current or former officer, director, trustee, key employee, creator or founder, substantial contributor, or 35% controlled entity or family member of any of these persons
.........
22
23
Secured mortgages and notes payable to unrelated third parties
..
23
24
Unsecured notes and loans payable to unrelated third parties
..
24
25
Other liabilities (including federal income tax, payables to related third parties, and other liabilities not included on lines 17 - 24).
Complete
Part X
of Schedule D
25
26
Total liabilities.
Add lines 17 through 25
..
204,045,574
26
234,982,056
Organizations that follow FASB ASC 958,
check here
and complete lines 27, 28, 32, and 33.
27
Net assets without donor restrictions
..........
20,518,990
27
21,554,594
28
Net assets with donor restrictions
...........
18,499,591
28
27,019,553
Organizations that do not follow FASB ASC 958,
check here
and complete lines 29 through 33.
29
Capital stock or trust principal, or current funds
.....
29
30
Paid-in or capital surplus, or land, building or equipment fund
...
30
31
Retained earnings, endowment, accumulated income, or other funds
31
32
Total net assets or fund balances
...........
39,018,581
32
48,574,147
33
Total liabilities and net assets/fund balances
........
243,064,155
33
283,556,203
Form
990
(2020)
Form 990 (2020)
Page
12
Part XI
Reconcilliation of Net Assets
Check if Schedule O contains a response or note to any line in this
Part XI
..............
1
Total revenue (must equal
Part VIII
, column (A), line 12)
............
1
300,986,746
2
Total expenses (must equal
Part IX
, column (A), line 25)
............
2
293,059,483
3
Revenue less expenses. Subtract line 2 from line 1
..............
3
7,927,263
4
Net assets or fund balances at beginning of year (must equal
Part X
, line 32, column (A))
..
4
39,018,581
5
Net unrealized gains (losses) on investments
...............
5
1,628,303
6
Donated services and use of facilities
.................
6
7
Investment expenses
.....................
7
8
Prior period adjustments
.....................
8
9
Other changes in net assets or fund balances (explain in Schedule O)
........
9
0
10
Net assets or fund balances at end of year. Combine lines 3 through 9 (must equal
Part X
, line 32, column (B))
10
48,574,147
Part XII
Financial Statements and Reporting
Check if Schedule O contains a response or note to any line in this
Part XII
.............
Yes
No
1
Accounting method used to prepare the Form 990:
Cash
Accrual
Other
If the organization changed its method of accounting from a prior year or checked "Other," explain in
Schedule O.
2a
Were the organization’s financial statements compiled or reviewed by an independent accountant?
2a
No
If ‘Yes,’ check a box below to indicate whether the financial statements for the year were compiled or reviewed on a separate basis, consolidated basis, or both:
Separate basis
Consolidated basis
Both consolidated and separate basis
b
Were the organization’s financial statements audited by an independent accountant?
2b
Yes
If ‘Yes,’ check a box below to indicate whether the financial statements for the year were audited on a separate basis, consolidated basis, or both:
Separate basis
Consolidated basis
Both consolidated and separate basis
c
If "Yes," to line 2a or 2b, does the organization have a committee that assumes responsibility for oversight
of the audit, review, or compilation of its financial statements and selection of an independent accountant?
2c
Yes
If the organization changed either its oversight process or selection process during the tax year, explain in Schedule O.
3a
As a result of a federal award, was the organization required to undergo an audit or audits as set forth in the Single Audit Act and OMB Circular A-133?
3a
Yes
b
If "Yes," did the organization undergo the required audit or audits?
If the organization did not undergo the required audit or audits, explain why in Schedule O and describe any steps taken to undergo such audits.
3b
Yes
Form
990
(2020)
Form 990 (2020)
Additional Data
Software ID:
Software Version:
Form 990, Special Condition Description:
Special Condition Description